Table 4.

Clinical performance of CA125, ROMA and MIA2G—all evaluable subjects by menopausal status

	CA125		ROMA		MIA2G
	Pre	Post	Pre	Post	Pre	Post
	(N = 506)	(N = 487)	(N = 506)	(N = 487)	(N = 506)	(N = 487)
Sensitivity, %	50.7	79.7	78.1	79.7	90.4	91.3
n/N	37/73	137/172	57/73	137/172	66/73	157/172
95% CI	39.5–61.8	73.0–85.0	67.3–86.0	73.0–85.0	81.5–95.3	86.1–94.6
Specificity, %	95.8	81.3	76.2	82.5	70	59.4
n/N	415/433	256/315	330/433	260/315	303/433	187/315
95% CI	93.5–97.4	76.6–85.2	72.0–80.0	78.0–86.3	65.5–74.1	53.9–64.6
Positive likelihood ratio	12.193	4.253	3.282	4.562	3.011	2.246
95% CI	7.353–20.217	3.338–5.418	2.666–4.041	3.547–5.868	2.561–3.541	1.950–2.587
Negative likelihood ratio	0.515	0.25	0.288	0.247	0.137	0.147
95% CI	0.407–0.650	0.185–0.338	0.186–0.445	0.183–0.333	0.068–0.278	0.090–0.240
Pre-test odds of ovarian malignancy	0.17–1	0.55–1	0.17–1	0.55–1	0.17–1	0.55–1
Post-test odds of ovarian malignancy with high risk score	2.06–1	2.32–1	0.55–1	2.49–1	0.51–1	1.23–1
Post test odds of no ovarian malignancy with low risk score	11.53–1	7.31–1	20.63–1	7.43–1	43.29–1	12.47–1
Positive test rate (as overall %)	10.9	40.2	31.6	39.4	38.7	58.5
False positive rate (as overall %)	3.6	12.1	20.4	11.3	25.7	26.3
False negative rate (as overall %)	7.1	7.2	3.2	7.2	1.4	3.1

CA125 high-risk cutoff: premenopausal subjects > 200 U/ml, postmenopausal subjects > 35 U/ml; ROMA high-risk cutoff: premenopausal subjects ≥ 11.4, postmenopausal subjects ≥ 29.9